Immunoembolization of Liver Metastases from Uveal Melanoma

David J. Eschelman; Marlana M. Orloff

doi:10.1055/s-0040-1718903

Digestive Disease Interventions, Table of Contents

Digestive Disease Interventions 2020; 04(04): 365-368
DOI: 10.1055/s-0040-1718903

Review Article

Immunoembolization of Liver Metastases from Uveal Melanoma

Authors

David J. Eschelman

¹Division of Interventional Radiology, Department of Radiology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania
Marlana M. Orloff

²Division of Solid Tumor, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania

Abstract

The authors review the use of immunoembolization as a liver-directed treatment for uveal melanoma metastatic to the liver.

Keywords

immunoembolization - liver metastases - uveal melanoma

Full Text

References

References
1 Aronow ME, Topham AK, Singh AD. Uveal melanoma: 5-year update on incidence, treatment, and survival (SEER 1973–2013). Ocul Oncol Pathol 2018; 4 (03) 145-151
2 Eschelman DJ, Gonsalves CF, Sato T. Transhepatic therapies for metastatic uveal melanoma. Semin Intervent Radiol 2013; 30 (01) 39-48
3 Grisanti S, Tura A. Uveal melanoma. In: Scott JF, Gerstenblith MR. eds. Noncutaneous Melanoma. Brisbane, Australia: Codon Publications; 2018: 1-18
4 Seedor RS, Eschelman DJ, Gonsalves CF. et al. An outcome assessment of a single institution's longitudinal experience with uveal melanoma patients with liver metastasis. Cancers (Basel) 2020; 12 (01) 117
5 Sato T, Nathan PD, Hernandez-Aya L. et al. Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: overall survival findings. J Clin Oncol 2018; 36: 9521
6 Helgadottir H, Höiom V. The genetics of uveal melanoma: current insights. Appl Clin Genet 2016; 9: 147-155
7 Yang J, Manson DK, Marr BP, Carvajal RD. Treatment of uveal melanoma: where are we now?. Ther Adv Med Oncol 2018; 10: 1758834018757175
8 Heppt MV, Amaral T, Kähler KC. et al. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. J Immunother Cancer 2019; 7 (01) 299
9 Kanai T, Monden M, Sakon M. et al. New development of transarterial immunoembolization (TIE) for therapy of hepatocellular carcinoma with intrahepatic metastases. Cancer Chemother Pharmacol 1994; 33 (Suppl): S48-S54
10 Yoshida T, Sakon M, Umeshita K. et al. Appraisal of transarterial immunoembolization for hepatocellular carcinoma: a clinicopathologic study. J Clin Gastroenterol 2001; 32 (01) 59-65
11 Saito T, Tsuchiya T, Sato Y. et al. Effect of transarterial immunoembolization as preoperative treatment for hepatocellular carcinoma. Ann Cancer Res Therap 2011; 19: 26-33
12 Nakamoto Y, Mizukoshi E, Kitahara M. et al. Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization. Clin Exp Immunol 2011; 163 (02) 165-177
13 Patel K, Sullivan K, Berd D. et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res 2005; 15 (04) 297-304
14 Sato T, Eschelman DJ, Gonsalves CF. et al. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2008; 26 (33) 5436-5442
15 Dranoff G, Jaffee E, Lazenby A. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993; 90 (08) 3539-3543
16 Sullivan KL. Immunoembolization for melanoma. In: Geschwind JFH, Soulen MC. eds. Interventional Oncology: Principles and Practice. New York: Cambridge University Press; 2008: 311-315
17 Sullivan KL, Aoyama T, Sato T, McCue P. Safety of immunoembolization of normal swine liver with human GM-CSF (granulocyte macrophage colony stimulating factor) and ethiodol. J Vasc Interv Radiol 2001; 12: S132-S133
18 Yamamoto A, Chervoneva I, Sullivan KL. et al. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology 2009; 252 (01) 290-298
19 Valsecchi ME, Terai M, Eschelman DJ. et al. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases. J Vasc Interv Radiol 2015; 26 (04) 523-32.e2
20 Gutjahr CJ, Gonsalves CF, Eschelman DJ, Frangos A, Meshekow JS, Sato T. Immunoembolization (IE) using 1500 mcg of granulocyte macrophage-colony stimulating factor (GM-CSF) and 2 million IU of interleukin-2 (IL-2) for the treatment of uveal melanoma (UM) hepatic metastases. J Vasc Interv Radiol 2014; 25: S26
21 Guez D, Eschelman D, Pan K. et al. Ipilimumab combined with immunoembolization for treatment of uveal melanoma metastatic to the liver. J Vasc Interv Radiol 2019; 30: S141
22 Ford R, Gonsalves C, Adamo R. et al. Prolonged survival after treatment of hepatic uveal melanoma metastases using immunoembolization. J Vasc Interv Radiol 2019; 30: S140